Peter Sadler from Warwick University, and collaborators at the Chinese Academy of Sciences have developed a ruthenium arene anticancer complex that inhibits the action of protein tyrosine phosphatase 1B, which regulates insulin levels.
In this Dalton Transactions Hot article the team investigate how the complex interacts with the active site of PTP1B by using a similiar shaped molecule as a model. Their compound was found to have an IC50 of 19 μM.
Read the full article for FREE until 2nd November to find out more about how this anticancer compound works…
Reactions of an organoruthenium anticancer complex with 2-mercaptobenzanilide—a model for the active-site cysteine of protein tyrosine phosphatase 1B
Yumiao Han, Qun Luo, Xiang Hao, Xianchan Li, Fuyi Wang, Wenbing Hu, Kui Wu, Shuang Lü and Peter J. Sadler
Dalton Trans., 2011, DOI: 10.1039/C1DT11189B